<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295240</url>
  </required_header>
  <id_info>
    <org_study_id>17-216</org_study_id>
    <nct_id>NCT03295240</nct_id>
  </id_info>
  <brief_title>The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma</brief_title>
  <official_title>Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of Venetoclax in combination with FDA
      approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I). This study will examine the
      effects Venetoclax has on participants when it is given in combination with BR-I.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">September 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related toxicity evaluated using CTCAE v4.0</measure>
    <time_frame>1 years</time_frame>
    <description>Participants symptoms will be evaluated using CTCAE v4.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>BR-I in combination with VEN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR-I (bendamustine, rituximab, ibrutinib)</intervention_name>
    <description>The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; day 1 and 2), rituximab (375 mg/m2; day 1), and ibrutinib (560 mg oral daily; day 1-28).</description>
    <arm_group_label>BR-I in combination with VEN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEN (Venetoclax)</intervention_name>
    <description>The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle.</description>
    <arm_group_label>BR-I in combination with VEN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Histologically confirmed MCL

          -  Relapse or progression after at least one systemic therapy for mantle cell lymphoma

          -  Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks
             prior to treatment in this study. If there is progression of disease on that therapy
             and all adverse effects have resolved to Grade 1 or baseline, in which case 2 weeks is
             acceptable.

          -  Palliative radiotherapy must have been discontinued 1 week prior to treatment in this
             study

          -  Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 2 weeks prior to receiving the first dose of study medication. If the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required.

          -  ECOG Performance Status 0-2

          -  Short-course corticosteroids are permissible in the following circumstances

               -  Short course systemic corticosteroids for disease control, improvement of
                  performance status or non-cancer indication (&lt; 10 days) must have been
                  discontinued prior to study treatment

               -  Ongoing administration of a stable dose of corticosteroid therapy (equivalent to
                  &lt;30 mg prednisone daily and previously received for &gt;/= 30 days) is permissible
                  provided there is evidence of measurable disease and there will be no increase in
                  steroid dose during the clinical trial.

          -  Adequate organ function and laboratory values within the following ranges:

          -  Absolute neutrophil count ? 1,000 cells/mm3 (1.0 x 109L), if neutropenia is due to
             bone marrow involvement absolute neutrophil count must be &gt;/= 500 cells.mm3 (0.5 x
             10^9/L)

          -  Platelet count ? 75,000 cells/mm3 (75 x 109/L), if thrombocytopenia I due to bone
             marrow involvement platelet count must be 50,000 cells/mm3

          -  Hemoglobin &gt; 8.0 g/dL

          -  Serum aspartate transaminase (AST) and alanine transaminase (ALT) &lt;/= 2.5 x upper
             limit of normal (ULN)

          -  Estimate creatinine clearance (Cockcroft-Gault) &gt;60 mL/min

          -  Bilirubin &lt;1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin)

          -  Patients who have been previously treated with BR are eligible, provided they did not
             progress during or within 6 months of completing BR treatment

          -  Patients who have undergone autologous stem cell transplant more than 3 months prior
             are eligible

          -  Patients who have undergone allogeneic stem cell transplant within 12 months, without
             active graft-versus-host-disease, and not on immunosuppression for prevention of
             graft-versus-host disease are eligible

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use a contraceptive method with a failure rate of &lt;1% per
             year during the treatment period and for at least 30 days after the last dose of
             venetoclax or 18 months after the last dose of rituximab, whichever is longer

               -  A woman is considered to be of childbearing potential if she is postmenarcheal,
                  has not reached a postmenopausal state (&gt;/= 12 continuous months of amenorrhea
                  with no identified cause other than menopause), and has not undergone surgical
                  sterilization (removal of ovaries and/or uterus).

               -  Examples of contraceptive method with a failure rate of &lt;1% per year include
                  bilateral tubal ligation, male sterilization, hormonal contraceptives that
                  inhibit ovulation, hormone-releasing intrauterine devices, and copper
                  intrauterine devices.

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm, as defined
             below:

               -  With female partners of childbearing potential, men must remain abstinent or use
                  a condom plus an additional contraceptive method that together result in a
                  failure rate of &lt;1% per year during the treatment period and for at least 6
                  months after the last dose of rituximab. Men must refrain from donating sperm
                  during this same period.

               -  With pregnant female partners, men must remain abstinent or use a condom during
                  the treatment period and for at least 6 months after the last dose of rituximab
                  to avoid exposing the embryo.

               -  The reliability of sexual abstinence should be evaluated in relation to the
                  duration of the clinical trial and the preferred and usual lifestyle of the
                  patient. Periodic abstinence e.g., calendar, ovulation, symptothermal, or
                  postovulation methods) and withdrawal are not acceptable methods of
                  contraception.

        Exclusion Criteria:

          -  Prior therapy with ibrutinib or venetoclax

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the opinion of the investigator, could compromise the subject's safety or put the
             study outcomes at undue risk.

          -  Unable to swallow capsules, malabsorption syndrome, disease significantly affecting
             gastrointestinal function, resection of the stomach or small bowel, symptomatic
             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
             obstruction or other condition that precludes enteral route of administration

          -  CNS involvement of the patientâ€Ÿs lymphoma

          -  Active HIV or hepatitis B or C with positive viral load, requiring anti-viral therapy

          -  Bleeding diathesis or use of warfarin or other vitamin K antagonist

          -  Prior history of infusion reactions or hypersensitivity to any of the study drugs

          -  Active concurrent malignancy requiring active therapy

          -  Pregnant or lactating females

          -  Patients who requires treatment with a potent cytochrome P450 (CYP) 3A inhibitor or
             inducer

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (excluding fungal infections of nail beds) at study enrollment, or any major episode
             of infection requiring treatment with IV antibiotics or hospitalization (relating to
             the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          -  Receipt of live-virus vaccines within 28 days prior to the initiation of study
             treatment or need for live-virus vaccines at any time during study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anita Kumar, MD</last_name>
    <phone>212-639-2668</phone>
    <email>kumara2@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anas Younes, MD</last_name>
    <phone>212-639-5059</phone>
    <email>younesa@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering @ Rockville</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kumar, MD</last_name>
      <phone>212-639-2668</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>17-216</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

